This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Citalopram and escitalopram associated dose-dependent QT interval prolongation

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Citalopram and escitalopram are associated with dose-dependent QT interval prolongation and should not be used in:

  • patients with congenital long QT syndrome or
  • known pre-existing QT interval prolongation combination with other medicines known to prolong the QT interval

ECG measurements should be considered for patients with cardiac disease, and electrolyte disturbances should be corrected before starting treatment.

New maximum daily doses New restrictions on the maximum daily dose of citalopram and escitalopram now apply (see Table below). Patients who currently take doses higher than the new recommended daily maximum should have their treatment reviewed.

New maximum doses for citalopram and escitalopram

Adults

Adults > 65 years of age

Adults with hepatic impairment

Citalopram

40mg*

20mg*

20mg*

Escitalopram

20mg

10mg*

10mg

*New (restricted) maximum daily dose.

Reference:

  1. Citalopram and escitalopram: QT interval prolongation - new maximum daily dose restrictions (including in elderly patients), contraindications and warnings. Drug Safety Update December 2011
  2. MeReC Monthly No. 47 (February 2012)

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.